Key Points
- Insider selling continued: Septerna insider Samira Shaikhly sold 2,178 shares on June 29 at an average price of $35.18, worth about $76,622. This follows several other recent sales totaling tens of thousands of shares.
- Stock has been strong recently: SEPN opened at $33.49, near its 52-week high of $37.99, and far above its 52-week low of $10.30. The company now has a market cap of about $1.51 billion.
- Analysts remain constructive: Recent broker updates included multiple price target increases, with targets ranging up to $60. Wall Street’s consensus rating is Moderate Buy with a consensus target price of $45.78.
Septerna, Inc. (NASDAQ:SEPN - Get Free Report) insider Samira Shaikhly sold 2,178 shares of the business's stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the sale, the insider directly owned 793 shares of the company's stock, valued at $27,897.74. This represents a 73.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Samira Shaikhly also recently made the following trade(s):
- On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The shares were sold at an average price of $35.08, for a total transaction of $219,250.00.
- On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The shares were sold at an average price of $28.93, for a total transaction of $171,699.55.
- On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The stock was sold at an average price of $30.06, for a total value of $354,647.88.
Septerna Stock Performance
Shares of SEPN stock opened at $33.49 on Wednesday. Septerna, Inc. has a fifty-two week low of $10.30 and a fifty-two week high of $37.99. The stock's fifty day moving average is $29.58 and its two-hundred day moving average is $27.49. The firm has a market capitalization of $1.51 billion, a P/E ratio of -41.35 and a beta of 2.39.
Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.23. The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. On average, equities analysts forecast that Septerna, Inc. will post -1.57 earnings per share for the current year.
Hedge Funds Weigh In On Septerna
Institutional investors and hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company's stock valued at $75,698,000 after buying an additional 1,260,409 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Septerna during the 1st quarter valued at approximately $21,334,000. First Light Asset Management LLC purchased a new stake in shares of Septerna during the 4th quarter valued at approximately $17,308,000. Primecap Management Co. CA acquired a new position in Septerna in the fourth quarter valued at approximately $15,225,000. Finally, Perceptive Advisors LLC purchased a new stake in Septerna in the second quarter valued at $5,723,000.
Analysts Set New Price Targets
Several brokerages recently issued reports on SEPN. Raymond James Financial upped their price objective on shares of Septerna from $47.00 to $53.00 and gave the company a "strong-buy" rating in a research note on Monday, June 8th. Stifel Nicolaus started coverage on Septerna in a report on Friday, May 1st. They set a "buy" rating and a $43.00 target price on the stock. Wells Fargo & Company boosted their target price on Septerna from $28.00 to $48.00 and gave the stock an "overweight" rating in a report on Tuesday, March 3rd. Guggenheim started coverage on Septerna in a research report on Thursday, June 11th. They issued a "buy" rating and a $52.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.78.
Check Out Our Latest Stock Report on Septerna
Septerna Company Profile
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
